Will the FDA give emergency use authorization or otherwise approve Molnupiravir before 2022?
PolymarketClosedCheck availabilityNo KYCVerified resolution dataWell calibratedThis market resolved: Yes
Limited resolution evidence
CoinRithm can show the recorded outcome, but not every settlement field is provider-verified.
Probability Timeline
Yes100%
No0%
Won
Lost
Rules
This market will resolve to “Yes” if, by December 31, 2021, 11:59:59 PM ET, Molnupiravir (also known under MK-4482, EIDD-2801 or Lagervio), or any product containing it receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19.
- Otherwise, this market will resolve to “No.”
- If the resolution source isn’t updated by the resolution date, credible news reports may be used instead.
- Molnupilavir, sold under the brand name Lagevrio among others, is an antiviral medication that inhibits the replication of certain RNA viruses, is used to treat COVID-19 in those infected by SARS-CoV-2 and is already approved by official health agencies in various countries (ie.
- UK, Bangladesh).